A better roadmap for beating a deadly leukemia

Using massive data set, OHSU researchers zero in on potential drug target to stop acute myeloid leukemia

By Joe Rojas-Burke August 09, 2022 Portland, Oregon

Downloads

Jeffrey Tyner, Ph.D., professor of cell, developmental and cancer biology in the OHSU School of Medicine. (OHSU/Christine Torres Hicks)

Jeff Tyner, Ph.D.

Jeffrey Tyner, Ph.D., co-led new research that zeros in on a potential drug target to stop acute myeloid leukemia. (OHSU/Christine Torres Hicks)

Shannon McWeeney, Ph.D.

Shannon McWeeney, Ph.D., professor and head of the Division of Bioinformatics and Computational Biology and an OHU Knight Cancer Institute researcher, Sept. 12, 2018. (OHSU/Kristyna Wentz-Graff)

Jeff Tyner group

(left to right): Nicola Long, Jeffrey Tyner, Ph.D., Kara Johnson, and Cristina Tognon, Ph.D. co-authored new research published in Cancer Cell. Their findings are the latest from the OHSU Knight Cancer Institutes Beat AML platform for analyzing the cancer cell gene expression, drug sensitivities, and medical outcomes of more than 800 people with acute myeloid leukemia. (OHSU/Christine Torres Hicks)

Research in the Tyner lab

Research in the Tyner lab (OHSU/Christine Torres Hicks)